Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 2, 2005, Pages 59-65

  Kitamura, Atsushi ^a   Mizuno, Yoshiko ^a   Natsui, Kiyoshi ^a   Yabuki, Masashi ^a   Komuro, Setsuko ^a   Kanamaru, Hiroshi ^a  

^a SUMITOMO CHEMICAL CO LTD   (Japan)

Author keywords

CYP2C8; CYP2D6; CYP3A4; In vitro metabolism; Perospirone

Indexed keywords

ANTISERUM; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ISOENZYME; KETOCONAZOLE; NEUROLEPTIC AGENT; PEROSPIRONE; QUERCETIN; QUINIDINE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; KINETICS; LIVER MICROSOME METABOLISM; MALE; MEAN RESIDENCE TIME; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGRESSION ANALYSIS; STEADY STATE;

ANTIBODIES, MONOCLONAL; ANTIPSYCHOTIC AGENTS; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; ISOENZYMES; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MODELS, CHEMICAL; QUERCETIN; QUINIDINE; THIAZOLES;

EID: 15544365344     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.432     Document Type: Article

References (30)

1. Hirose A, Kato T, Ohno Y, et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine-2 and dopamine-2 antagonistic actions. Jpn J Pharmacol 1990; 53: 321-329.
2. Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol. Clin Evaluation 1997; 24: 159-205.
3. 4C-SM-9018 to rats. Clin Report 1997; 31: 689-705.
4. Fujimoto K, Mizuno Y, Kanamaru H, Nakatsuka I. Identification of metabolites of perospirone. Clin Report 1997; 31: 581-657.
5. Inanaga K, Irie S, Urae Y, Urae T. Phase I study of perospirone HCl (SM-9018). Clin Report 1997; 31: 2113-2157.
6. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165-183.
7. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
8. Mizuno Y, Tani N, Komuro S, Kanamaru H, Nakatsuka I. In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet 2003; 28: 59-66.
9. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 2004; 32: 973-982.
10. Mizuno Y, Kanamaru H, Nakatsuka I, Nakayama H. Disposition of SM-9018 after single oral administration to rats and protein binding to serum of human and animals. Clin Report 1997; 31: 543-568.
11. 14C]SM-9018 in cynomolgus monkeys. Clin Report 1997; 31: 799-809.
12. 14C]SM-9018 in cynomolgus monkeys. Clin Report 1997; 31: 811-819.
13. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alphahydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
14. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
15. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
16. Houston JB, Kenworthy KE. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 2000; 28: 246-254.
17. Ong CE, Coulter S, Birkett DJ, Bhasker CR, Kiners JO. The xenobiotic inhibitor profile for cytochrome P4502C8. Br J Clin Pharmacol 2000; 50: 573-580.
18. Li Y, Wang E, Patten CJ, Chen L, Yang CS. Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab Dispos 1994; 22; 566-571.
19. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001; 4: 217-227.
20. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300: 399-407.
21. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001; 29: 23-29.
22. Shimada T, Yamazaki M, Mimura M, Inui K, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
23. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
24. van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25: 707-712.
25. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522.
26. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428-437.
27. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 Suppl 1: 35S-42S.
28. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000; 49 Suppl 1: 71S-76S.
29. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
30. Shimakura J, Tani N, Mizuno Y, Komuro S, Kanamaru H. In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 2003; 28: 67-72.